Health Insurance Paid Costs and Drivers of Costs for Patients with Crohn's Disease in the United States

American Journal of Gastroenterology

Volumn 111, Issue 1, 2016, Pages 15-23

  Park, K T ^a   Colletti, Richard B ^b   Rubin, David T ^c   Sharma, Bal K ^d   Thompson, Amy ^d   Krueger, Andrew ^d  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d CVS Caremark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GASTROENTEROLOGIST; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH INSURANCE; HOSPITAL UTILIZATION; HUMAN; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MIDDLE AGED; NEWBORN; OUTPATIENT CARE; PHARMACY; PRESCHOOL CHILD; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX DIFFERENCE; UNITED STATES; VERY ELDERLY; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; COMPLICATION; ECONOMICS; HOSPITALIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INSURANCE, HEALTH; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; YOUNG ADULT;

EID: 84955368440     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.207     Document Type: Article

References (21)

1. Cummings JR, Keshav S, Travis SP. Medical management of Crohn's disease. BMJ 2008; 336: 1062-6.
2. Sonnenberg A. Demographic characteristics of hospitalized IBD patients. Dig Dis Sci 2009; 54: 2449-55.
3. Gunnarsson C, Chen J, Rizzo JA et al. Direct health care insurer and outof-pocket expenditures of infl ammatory bowel disease: evidence from a US national survey. Dig Dis Sci 2012; 57: 3080-91.
4. Kappelman MD, Porter CQ, Galanko JA et al. Utilization of healthcare resources by U. S. children and adults with infl ammatory bowel disease. Infl amm Bowel Dis 2011; 17: 62-8.
5. San Roman AL, Munoz F. Comorbidity in infl ammatory bowel disease. World J Gastroenterol 2011; 17: 2723-33.
6. Kappelman MD, Rifa-Shiman SL, Porter CQ et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135: 1907-13.
7. Rubin DT, Mody R, Davis KL et al. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Th er 2014; 39: 1143-55.
8. Gibson TB, Ng E, Ozminkowski RJ et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008; 50: 1261-72.
9. Everett SM, Hamlin PJ. Evidence-based use of anti-TNF therapy in Crohn's disease; where are we in 2011? Frontline Gastroenterol 2011; 2: 144-50.
10. Park KT, Sin A, Wu M et al. Utilization trends of anti-TNF agents and health outcomes in adults and children with infl ammatory bowel diseases: a single-center experience. Infl amm Bowel Dis 2014; 20: 1242-9.
11. van der Valk ME, Mangen MJ, Leenders M et al. Healthcare costs of infl ammatory bowel disease have shift ed from hospitalisation and surgery towards anti-TNF? therapy: results from the COIN study. Gut 2014; 63: 72-9.
12. Feagan BG, Vreeland MG, Larson LR et al. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol 2000; 95: 1955-60.
13. Kurina LM, Goldacre MJ, Yeates D et al. Depression and anxiety in people with infl ammatory bowel disease. J Epidemiol Community Health 2001; 55: 716-20.
14. Kulnigg S, Gasche C. Systemic review: managing anemia in Crohn's disease. Aliment Pharmacol Th er 2006; 24: 1507-23.
15. Park KT, Bass D. Infl ammatory bowel disease-attributable costs and costeff ective strategies in the United States: A review. 2011. Infl amm Bowel Dis 2011; 17: 1603-9.
16. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-83.
17. Park KT, Crandall WV, Fridge J et al. Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in infl ammatory bowel disease. Infl amm Bowel Dis 2014; 20: 946-51.
18. Health Care Cost Institute (HCCI). Changes in health care spending in 2012. A summary of HCCI's Health Care Cost and Utilization Report, Issue Brief #3. September 2012
19. Gomollon F. Biosimilars in infl ammatory bowel disease: ready for prime time? Curr Opin Gastroenterol 2015; 31: 290-5.
20. Greene JA. Generic: The Unbranding of Modern Medicine John Hopkins University Press: Baltimore, 2014.
21. Rinaudo-Gaujous M, Paul S, Tedesco ED et al. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Th er 2013; 38: 914-24.